A proof-of-concept trial led by the Universities of Birmingham and University Hospitals Birmingham NHS Foundation Trust has identified an antibody drug that may offer benefit for some patients hospitalized with COVID-19 pneumonia. The CATALYST trial tested UK-based bio-pharmaceutical company Izana Bioscience’s namilumab (IZN-101) (image) as a potential therapeutic to treat patients who are hospitalized with COVID-19 pneumonia, and receiving “usual” care, as well as having high levels in their blood of a marker of inflammation known as C reactive protein (CRP). CRP levels rise when there is inflammation in the body, and elevated levels of CRP have been found to be a potential early marker to predict risk for severity of COVID-19.
Login Or Register To Read Full Story